Relationship of histopathologic subtype with 18F-FDG uptake and EGFR mutations i
PUBLISHED: 2015-11-26  1728 total views, 2 today

Guangliang Qiang1, Chaoyang Liang1, Rui Xu2, Jue Yan2, Yanyan Xu3Ye Wang4, Jiping Da4, Bin Shi1, Yongqing Guo1, Deruo Liu1

1Department of Thoracic Surgery, China-Japan Friendship Hospital, 2Department of Nuclear Medicine, China-Japan Friendship Hospital, 3Department of Radiology, China-Japan Friendship Hospital, 4Department of Pathology, China-Japan Friendship Hospital


Objective:The aim of this study is to investigate the correlation of histopathologic subtypes with epidermal growth factor receptor (EGFR) mutations and 18F-fluorodeoxyglucose (FDG) uptake in lung adenocarcinomas (ADCs). Method: A total of 97 patients with ADC who underwent 18F-FDG positron emission tomography (PET)/CT scan prior to surgical resection were retrospectively reviewed. All cases were divided according to the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification, and graded by histopathologic scoring system. EGFR mutations were identified as well. Clinicopathological factors associated with EGFR mutation status were evaluated by univariate and multivariate analysis. Result:The frequency of EGFR mutation was 45.4% and associated with gender, smoking, maximum standardized uptake value (SUVmax) and histopathologic score. ADC patients with low SUVmax were more likely to carry EGFR mutations than those with high SUVmax (P=0.018), and patients with lower histopathologic score showed significantly lower SUVmax than those with higher score (P<0.001). Moreover, histopathologic score and smoking history were found to be independent predictors for EGFR mutation according to multivariate logistic regression analysis. Conclusion: SUVmax and EGFR mutations correlate to the stratification of lung ADCs based on the IASLC/ATS/ERS classification. SUVmax promises a useful marker in stratifying preoperative patients with lung ADCs and identifying EGFR mutations in case of unavailable molecular diagnostics.

 

Key Words: Adenocarcinoma  Histologic subtype  Epidermal growth


Copyright © 1998 - 2024 Chinese Society of Clinical Oncology(CSCO). All Rights Reserved

京公网安备 11010502031031号

Contact Us

EMAIL:office@csco.org.cn

international@csco.org.cn

Phone:86(10)67726451 (Beijing)

86(25)84547290 (Nanjing)